clinical stage life sciences venture capital investor

EnteroMedics’ vBloc® Neurometabolic Therapy Recognized at 2017 Edison Awards

EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced it has been named a 2017 Bronze Edison Award Winner by the internationally renowned Edison Awards™ in the Health and Wellness category for its vBloc® Neurometabolic Therapy for the treatment of obesity. TheContinue Reading

Takeda Completes Enrollment of More Than 20,000 Children and Adolescents in Global Phase 3 Trial of Dengue Vaccine Candidate

– Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluates the efficacy of two doses of vaccine candidate TAK-003, administered three months apart, to protect against all four strains of dengue virus, regardless of previous dengue exposure – Study includes children and adolescents ages 4 through 16 years in eight dengue-endemic countries across Latin America andContinue Reading

Visioneering Technologies, Inc. Successfully Lists on ASX

Visioneering Technologies, Inc. (ASX:VTI) lists on the Australian Securities Exchange (ASX) VTI received strong institutional and retail investor support raising AUD$33.3 million in fully underwritten IPO VTI has developed a proprietary daily disposable contact lens called NaturalVue® (etafilcon A) Multifocal 1 Day contact lenses (NaturalVue MF) used in two major vision care applications – lossContinue Reading

US Medical Device Company Visioneering Technologies, Inc. to List On ASX – Initial Public Offer Opens

Visioneering Technologies, Inc. (VTI) has developed a proprietary daily disposable contact lens called NaturalVue™ (etafilcon A) Multifocal 1 Day Contact Lenses (NaturalVue MF) used in two major vision care applications – presbyopia (age-related loss of near-vision) and paediatric myopia (near-sightedness in children) NaturalVue MF has been cleared by the FDA and is already available inContinue Reading

Amaranth Medical Initiates Trial of Sub-100-Micron MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold

Amaranth Medical, a privately held medical device company, announced the initiation of a clinical study of the Company’s latest-generation MAGNITUDE™ sirolimus-eluting bioresorbable scaffold (BRS) scaffold, which has a strut thickness in the sub-100-micron range. Dr. Antonio Colombo, director of the Hemodynamics Division at Ospedale San Raffaele in Milan, Italy and Dr. Juan F. Granada, executiveContinue Reading

Amaranth Medical 9-Months Clinical and Imaging Results of the FORTITUDE Sirolimus-Eluting Bioresorbable Scaffold Presented at TCT

Amaranth Medical, a privately held medical device company, announced that a presentation of the 9-month clinical and imaging results from the company’s FORTITUDE® sirolimus-eluting bioresorbable scaffold (BRS) took place during the First Report Investigations session at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium on Monday, October 31st. Dr. Antonio Colombo, co-principal investigator and directorContinue Reading

vBloc Institute Demonstrates Positive Clinical Success in Patients Struggling with Weight Loss as Compared to Pivotal FDA Trial with EnteroMedics vBloc(R) Therapy in Combination with vBloc(R) Achieve Program

EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced clinical success at the Bariatric Center at Sky Ridge Medical Center in Colorado, a vBloc Institute partner, where several vBloc procedures have been performed to date by Frank H. Chae, MD, FACS,Continue Reading

Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003)

Study to evaluate vaccine protection against all four strains of dengue virus, regardless of previous exposure. Takeda Pharmaceutical Company Limited, (“Takeda”) today announced that it has vaccinated the first subject in the Tetravalent Immunization against Dengue Efficacy Study (TIDES), a Phase 3 double-blind, randomized and placebo-controlled trial of its live-attenuated tetravalent dengue vaccine candidate (TAK-003).Continue Reading